logo

For the Inventor, By the Inventor

New York, NY, United States of America

Intercept Pharmaceuticals, Inc.


USPTO Granted Patents = 62

% Expired Patents = 25.8



Trademarks = 8

Forward Citations = 265

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Roberto Pellicciari (40 out of 66 patents)

silverMedal Mark Pruzanski (15 out of 15 patents)

bronzeMedal Antimo Gioiello (10 out of 10 patents)

4.  Stefano Fiorucci (8 out of 16 patents)

5.  Emma Sharp (6 out of 11 patents)

6.  Alex Eberlin (6 out of 21 patents)

7.  André Steiner (6 out of 6 patents)

8.  Emilie Jolibois (6 out of 6 patents)

9.  Heidi Waenerlund Poulsen (6 out of 6 patents)

10.  Melissa Rewolinski (6 out of 7 patents)

11.  Ralf Gross (6 out of 6 patents)

12.  Fiona Dubas-Fisher (6 out of 6 patents)

13.  Mitsuhiro Matono (5 out of 8 patents)

14.  Kay Olmstead (4 out of 19 patents)

15.  Gabriel Galvin (4 out of 7 patents)


Core Competencies:
Bile Acid Derivatives
Farnesoid X Receptor
TGR5 Modulators
Obeticholic Acid
Combination Therapy
Cancer Treatment
Fibrosis
Steroid Agonists
Pharmaceutical Compositions
Hepatic Regeneration
Isotopically Labeled Compounds
3-Desoxy Derivative

62 patents:

1. 12337003 - Pharmaceutical compositions for combination therapy (2025-06-24),
2. 12291549 - Farnesoid X receptor modulators (2025-05-06),
3. 11807659 - TGR5 modulators and methods of use thereof (2023-11-07),
4. 11472831 - Isotopically labeled bile acid derivatives (2022-10-18),
5. 11419878 - Medicine obtained by combining FXR agonist and ARB (2022-08-23),
6. 11413295 - Oral preparation of obeticholic acid (2022-08-16),
7. 11345721 - TGR5 modulators and methods of use thereof (2022-05-31),
8. 11319337 - 3-desoxy derivative and pharmaceutical compositions thereof (2022-05-03),
9. 11311557 - Pharmaceutical compositions for combination therapy (2022-04-26),
10. 11072631 - Methods and intermediates for the preparation bile acid derivatives (2021-07-27),
11. 11066437 - Methods and intermediates for the preparation of bile acid derivatives (2021-07-20),
12. 11034717 - Farnesoid X receptor modulators (2021-06-15),
13. 11000532 - Farnesoid x receptor modulators (2021-05-11),
14. 10987362 - Treatment of fibrosis using FXR ligands (2021-04-27),
15. 10894054 - FXR agonist compositions for combination therapy (2021-01-19),
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. The company's primary focus is on the development and commercialization of obeticholic acid (OCA), a first-in-class bile acid receptor agonist.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Intercept Pharmaceuticals, Inc.
62 Patents

#160 in New York, NY

#348 in New York

#5,836 in US

#11,746 in the World

New York, NY (US)
New York, NY, United States of America

Intercept Pharmaceuticals, Inc.

Forward Citations = 265

61 inventors:

goldMedal Roberto Pellicciari (40 out of 66 patents)

silverMedal Mark Pruzanski (15 out of 15 patents)

bronzeMedal Antimo Gioiello (10 out of 10 patents)

4.  Stefano Fiorucci (8 out of 16 patents)

5.  Emma Sharp (6 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…